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clinical benefit of anti-cancer therapies based on comparable
parameters while upholding accountability for reasonableness.
Both platforms represent very important tools to ensure the ap-
propriate use of limited resources in delivering cost-effective and
more affordable cancer care globally.
Inarguably, data weighted and reported in these evolving scor-
ing systems will help to identify those therapies with proven clini-
cal benefit and guide clinical decision-making and provide
physicians, patients and their families with independent, bal-
anced information.
Guided by evidence-based data reported through the ASCO
and ESMO frameworks, decision makers will need to balance
efficacy and reimbursement of anti-cancer treatments with re-
gional socio-economic realities. In parallel, professional societies
and organizations, including ASCO and ESMO, have a shared
responsibility to help map these necessary directions.
In our dedicated efforts to improve oncology practice and
promote quality and high-value cancer care for all our patients,
we can and will do better.
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On the need to adjust for multiplicity in
confirmatory clinical trials with master
protocols
Recent advances in tumor biology and targeted therapies have led
to clinical trials assessing treatment efficacy in multiple patient
populations or subgroups using a master protocol [1]. These can
lead to efficiency gains by testing several statistical hypotheses in
the same clinical trial.
Although much of the development of novel design
approaches has been in exploratory phase II trials that may not
include a control group, there is growing interest in such methods
in confirmatory randomized controlled trials. These might be
phase III trials with subgroup analyses or phase II/III trials com-
bining exploratory and confirmatory elements. In these settings,
multiple hypothesis tests can lead to statistical error rate inflation.
A recent Food and Drug Administration draft guidance [1] notes
the risk of ‘potential overinterpretation of findings’, but offers no
clear suggestions as to when statistical correction for multiplicity
should be implemented.
Before considering multiplicity adjustment, we first describe
some recently used innovative designs. Our aim is not to give a
comprehensive review, but to illustrate key relevant concepts.
Based on the principle that correction is necessary when there are
multiple opportunities to make a (regulatory) claim of efficacy
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for a particular treatment in any population or subgroup [2, 3],
we propose when corrections are needed if the innovative designs
are used in confirmatory trials.
Interest in stratified medicine has led to subgroup selection, or
treatment interaction, trials [4] comparing one or more experi-
mental treatments with a control treatment in a population com-
prising two or more pre-defined subgroups, for example based
on biomarker levels. Such trials assess treatment efficacy in the
whole population and the subgroups.
Examples of these trials include the Gefitinib versus docetaxel
in previously treated non-small-cell lung cancer (INTEREST)
trial [5] that assessed non-inferiority in the overall population
and superiority in high epidermal growth factor receptor
(EGFR)-gene-copy patients, and the Biomarker-integrated
Approaches of Targeted Therapy for Lung Cancer Elimination 1
(BATTLE 1) trial [6], a phase II trial comparing four non-small-
cell lung cancer treatments in five biomarker-defined subgroups
to determine the best treatment for each subgroup.
Subgroup selection trials may also include interim analyses to
decide whether recruitment should continue from the whole
population or be restricted to one or more subgroups where the
experimental treatment appears most effective, as in an adaptive
enrichment design [7–9].
When experimental treatment options depend on one or more
biomarkers within a single cancer type, several treatments may be
evaluated in parallel in an umbrella trial [1]. If each experimental
treatment is evaluated in a single subgroup, the parallel sub-
studies are essentially independent trials, each considering one
treatment in its own distinct patient group, conducted together
for administrative or operational reasons such as saving time, re-
ducing costs or facilitating recruitment.
The sub-studies, which are often randomized, could be two-
arm comparisons, each comparing one experimental treatment
to a control, or multi-arm comparisons of several drugs within
each sub-study. An example of the former is FOCUS4: a molecu-
larly stratified trial programme in colorectal cancer [10] which
included randomized sub-studies of a different experimental
treatment in each of five biomarker-defined subgroups, with
early stopping for futility. The Biomarker-Driven Protocol for
Accelerating Development of Therapies for Squamous Cell Lung
Cancer (Lung-Map) trial [11] has a similar design, with different
treatments assessed in parallel in marker-specific subgroups.
The development of therapies targeting a particular mutation
that may be present in multiple tumor types has led to the basket
trial design.
Some authors [1, 12] use this term for a trial in which patients
with a common mutation are recruited from populations with
different tumor types. The effect of the experimental treatment
can then be assessed both in the whole recruited group and in the
individual tumor types. Often such trials are small and non-
randomized, with all patients receiving the experimental
treatment.
An example of such a trial is the imatinib study B2225 [13].
This open-label phase II trial investigated the effect of imatinib in
patients expressing imatinib-sensitive tyrosine kinases in 40 dif-
ferent life-threatening malignancies, including solid tumors and
hematologic malignancies.
The term basket trial has also been used to describe a more
complex trial in which recruited patients have different tumor
types and different mutations [14]. Patients are then assigned
to experimental treatments according to their mutation.
Acknowledging that this type of design extends the simpler defi-
nition to include more than one mutation type, such a trial has
also been called a matrix trial, although this term has also been
used more generally, including both basket and umbrella trials as
special cases.
An example of a matrix trial is the National lung matrix trial
[15] in which seven drugs are evaluated in 18 targeted molecular
cohorts, with drugs evaluated in one to five cohorts.
Multiplicity issues may arise when multiple hypothesis tests are
conducted, particularly in confirmatory trials. Conventionally,
adjustments are made when multiple confirmatory hypothesis
tests are conducted in a trial [16], but not when they are con-
ducted in separate trials. This position has arisen mainly in sim-
pler settings than those now being developed, and the use of
innovative trial designs has led to reconsideration of multiplicity
issues, with little current consensus [2, 3, 17].
In the confirmatory setting, a basic principle is that correction
for multiplicity is needed if testing of multiple hypotheses,
whether through testing in multiple subgroups or at interim anal-
yses, leads to multiple opportunities to inform a single claim of
effectiveness for a drug [2].
In considering multiplicity issues in trials testing hypotheses
based on different subgroups, as in the examples above, it is help-
ful to differentiate between trials on the basis of the role of the
subgroups. We will consider three cases illustrated in Figure 1
and discussed in detail in the next three paragraphs.
We use the term subgroups within treatment arms to describe a
setting in which the population is divided into subgroups, but in
which the subgroup classification does not determine the experi-
mental treatment options. In a non-randomized setting, all
patients receive the same experimental treatment. In a random-
ized setting, all patients are randomized between the same two or
more treatments, usually including a control (Figure 1A). The
trial then assesses the effect of the same experimental treat-
ment(s) in a number of subgroups. In this setting, since patients
in different subgroups can receive the same experimental treat-
ment(s), testing might also be conducted with subgroups com-
bined as well as in individual subgroups.
This situation may be contrasted with one in which we have
treatment arms within subgroups, when the population is divided
into subgroups with distinct experimental treatment options
available to each. In a non-randomized trial, the treatment is de-
termined by the subgroup classification, and in a randomized
trial, the treatments available for randomization depend on the
subgroup so that randomization can only be undertaken for a pa-
tient once their subgroup is known (Figure 1B). The trial then
assesses the effects of a number of experimental treatments, each
in its corresponding subgroup.
An extension of the two settings above occurs when a trial
includes subgroups of both types; in this case, subgroups are de-
fined in two ways, with one of these restricting experimental treat-
ment options, giving subgroups within treatment arms within
subgroups (Figure 1C). An example is a situation in which patients
are classified by two biomarkers, biomarker 1 and biomarker 2,
with the experimental treatment depending on biomarker 1 but
not on biomarker 2. Patients with a positive biomarker 1 status
might then be allocated to treatment A, or randomized between A
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and a control treatment C, and biomarker 1 negative patients be
allocated to treatment B or randomized between B and C, in each
case irrespective of biomarker 2 status. The trial then assesses
treatment A in two subgroups of biomarker 1-positive patients
who are either positive or negative for biomarker 2 and treatment
B in two subgroups of biomarker 1-negative patients who are ei-
ther positive or negative for biomarker 2.
Our aim is to correct for multiplicity when multiple hypothesis
testing increases the chance of erroneously declaring a given inef-
fective treatment to be effective in all or some part of the popula-
tion, but not for multiple hypothesis testing for different
treatments when the use of each is restricted to a single subgroup.
Using the definitions introduced above, we therefore propose that
multiplicity corrections should be used in the setting with sub-
groups within treatment arms, or for the subgroups within treatment
arms within subgroups, including the case of testing in combina-
tions of subgroups, but not with treatment arms within subgroups.
Our rationale is that with subgroups within treatment arms, the
same treatment is evaluated in a number of subgroups, giving
multiple opportunities to claim this treatment is effective. This
contrasts with the treatment arms within subgroups setting, where
each experimental treatment is considered for only one subgroup
so that there are not multiple opportunities for an effectiveness
claim for any particular treatment.
The following paragraphs illustrate the application of this pro-
posed multiple testing strategy in the designs introduced
previously.
In subgroup selection, treatment interaction or adaptive en-
richment designs the aim is to assess the experimental treat-
ment(s) in the whole population and/or in one or more
subgroups. As treatment options are not determined by subgroup
classification, we have subgroups within treatment arms. In a con-
firmatory trial setting, our proposal is therefore to adjust for mul-
tiplicity arising from hypothesis testing in multiple subgroups in
such a trial, for example using a Holm–Bonferroni correction
[18], or a method allowing for overlapping subgroups [19].
In umbrella trials, we have treatment arms within subgroups.
Our proposal would therefore be to not adjust for multiplicity
arising from the testing of multiple hypotheses in different sub-
groups. This proposal is consistent with the view that the sub-
studies, though run under a single protocol, are essentially inde-
pendent trials, as each subgroup receives a different experimental
treatment so that the efficacy of each treatment is assessed only
once.
In the simpler type of basket trial [12] one experimental treat-
ment is evaluated in patients with different tumor types. We thus
have subgroups within treatment arms. In a confirmatory trial, we
would therefore propose adjustment for multiplicity arising from
hypothesis testing in the different tumor types to protect the
overall chance of erroneously claiming effectiveness of the experi-
mental treatment.
In matrix trials or the more complex type of basket trial with
distinct treatments tested in different mutations [14], we have
subgroups (e.g. tumor types) within treatment arms within
Figure 1. Designs for clinical trials with master protocols: (A) with subgroups within treatment arms; (B) with treatment arms within subgroups;
(C) with subgroups within treatment arms within subgroups.
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subgroups (e.g. mutations). In confirmatory trials, we would
therefore propose adjustment for the multiple hypothesis tests of
the effectiveness of the same treatment in different tumor types,
but not for testing in different mutations since mutation deter-
mines treatment.
Although we have focused on specific trial settings, the princi-
ples are generalizable. For example, the same design might be
used if subgroups are specified not by a molecular biomarker but
by another measurable patient characteristic that determines
treatment. Similarly, the same design might be used in a trial not
just with multiple tumor types, but also with subgroups defined
by some other factor in which we are trying to ascertain sub-
groups for which a treatment is effective, requiring multiplicity to
be handled in the same way. Consideration of the same concepts
could also enable application of the novel trial designs in other
therapeutic areas.
We have focused on multiplicity arising from multiple sub-
groups. Trials, including platform or multi-arm multi-stage tri-
als, may also include multiple treatments, possibly in addition to
multiple subgroups. Multiplicity issues in such settings are dis-
cussed elsewhere [3, 17]. The need for multiplicity correction
depends on the relatedness of the hypotheses being tested. If dif-
ferent doses of the same drug are tested, multiplicity corrections
will be more appropriate than when multiple arms are unrelated
treatments, possibly with different modes of action, whether or
not they are compared with a common control group. Error rates
other than familywise error rates, including false discovery rates
and family multiple error rates, could also be considered in such
settings [3].
Multiplicity arising from testing a single treatment in a number
of different indications could also be considered, as could meth-
ods for testing a treatment strategy using data from multiple sub-
groups each receiving a different experimental treatment [20].
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